BIO-TECHNE ANNOUNCES OPENING OF NEW IMMUNOASSAY MANUFACTURING FACILITY
Bio-Techne Corporation (NASDAQ: TECH) has opened a new 52,000 sq. ft. product innovation and manufacturing facility in Wallingford, Connecticut, doubling its operational footprint. This facility enhances Ella™ immunoassay cartridge production capacity five-fold, enabling production of up to 500,000 cartridges annually. The expansion, featuring one of the largest cleanrooms in the area, aims to meet the rising global demand for rapid and precise biomarker detection. The Ella assays, developed by R&D Systems, support diverse research areas and are expected to experience continued demand growth.
- Expansion of facility increases production capacity to 500,000 cartridges per year.
- Facility enhances Ella™ immunoassay cartridge production five-fold.
- Supports growing global demand for rapid and precise biomarker analysis.
- None.
MINNEAPOLIS, Nov. 15, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing facility. The expansion more than doubles the operational footprint at Bio-Techne's Wallingford, Connecticut site and provides a five-fold increase in Ella™ immunoassay cartridge production capacity. Ella is an automated multiplexing immunoassay system, that enables rapid and hands-free precision biomarker detection.
With increased laboratory, manufacturing, and cleanroom space, the new facility increases production capacity to 500,000 cartridges per year. This enables Bio-Techne to meet growing global demand for its reproducible immunoassays capable of delivering rapid, precision multiplexing for biomarker analysis. Boasting one of the largest cleanrooms in the region, the new facility increases Bio-Techne's cleanroom space to 9,500 square feet. Following extensive quality validation procedures, the facility is now fully operational.
Ella assays are powered by R&D Systems®, a Bio-Techne brand, the recognized 30-year global leader for high quality antibodies, proteins, and ELISA kits. Ella has a rapidly growing assay menu consisting of over 200 analytes to support research across neuroscience, cell and gene therapy, immunology, oncology and other areas of research activities. Ella, and the family of miniaturized, microfluidic cartridges, delivers precision multiplex immunoassay results, providing a robust solution for simple and reliable biomarker analysis in research and clinical applications.
"We anticipate demand for our Ella assays to continue to grow as researchers have an increasing need for the speed, precision, and efficiency advantages inherent in a hands-free immunoassay workflow," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "This expanded immunoassay cartridge capacity positions Bio-Techne to meet current and future global demand for automated, high-quality, extremely sensitive and highly reproducible immunoassays run on our Ella system."
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations
david.clair@bio-techne.com
612-656-441
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-opening-of-new-immunoassay-manufacturing-facility-301676842.html
SOURCE Bio-Techne Corporation
FAQ
What is the significance of Bio-Techne's new facility opening on Nov. 15, 2022?
How much has Bio-Techne increased its manufacturing capacity with the new facility?
What is Ella™ and why is its production capacity important for Bio-Techne?
What are the future expectations for demand regarding Ella assays?
What advancements come with the new Bio-Techne facility?
